We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Calcium Binder Use for Kidney Disease Questioned

By HospiMedica International staff writers
Posted on 29 Jul 2013
A new study challenges the common clinical practice of prescribing high doses of calcium to patients with chronic kidney disease (CKD).

Researchers at the University of Toronto (ON, Canada) and the University of Alberta (Edmonton, Canada) conducted a systematic review of randomized and nonrandomized trials that compared outcomes between patients with CKD taking calcium-based phosphate binders, with those taking non-calcium-based binders. More...
The researchers identified all articles published in any language after Aug 1, 2008, up until Oct 22, 2012, by searching Medline, Embase, International Pharmaceutical Abstracts, Cochrane Central Register of Controlled Trials, and Cumulative Index to Nursing and Allied Health Literature.

In all, the researchers identified 847 reports; an analysis of the 11 randomized, controlled trials involving 4,622 patients which met the inclusion criteria showed that patients assigned to non-calcium-based binders, such as sevelamer or lanthanum, had a 22% reduction in all-cause mortality compared with those assigned to calcium-based phosphate binders, as well as reduced calcification of coronary arteries. The study was published early online on July 19, 2013, in the Lancet.

“Doctors commonly prescribe calcium supplements to prevent elevated phosphate levels, which can damage the body, but a growing number of studies have shown calcium supplements may actually increase the risk of heart disease,” said lead author Sophie Jamal, MD, of the University of Toronto. “Our study validates these claims and, for the first time, shows the long-term consequences of taking calcium supplements can be dangerous for patients with kidney disease.”

“What we can say is that the risk of death is lower in those taking non-calcium-based treatments; what we don't know is the exact mechanism of this finding and whether it is that calcium is bad, or that sevelamer and lanthanum are good,” added senior author Ross Tsuyuki, MD, of the University of Alberta. “Some researchers and physicians have been saying for years that kidney disease patients need to get off calcium. Now we think our review shows there is much more solid evidence to argue for that change to clinical practice.”

Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphatemia in patients with CKD. Calcium binds to the phosphate in the body, eliminating it via the kidneys to the urine. Sevelamer or lanthanum can also get rid of phosphate in the body, but are much more expensive, costing up to 100 times more than calcium.

Related Links:

University of Toronto
University of Alberta



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.